featured
A Recap of Key New Data in Breast Cancer
Interview by
Interview with
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Robson ME, Im S-A, Senkus E, et al. OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm). Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract LBA4.
- Sledge GW, Toi M, Neven P, et al. MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2- advanced breast cancer who progressed on endocrine therapy. Paper presented at: American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL. Abstract 1000.
Disclosure statements are available on the authors' profiles: